Author:
Dombrowski Stefan C.,Gischlar Karen L.,Mrazik Martin
Reference83 articles.
1. Addington, A. M., Gornick, M. C., Shaw, P., Seal, J., Gogtay, N., Greenstein, D., et al. (2007). Neuregulin 1 (8p12) and childhood-onset schizophrenia: Susceptibility haplotypes for diagnosis and brain developmental trajectories. Molecular Psychiatry, 12, 195–205.
2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., rev.). Washington, DC: Author.
3. American Psychiatric Association. (2010). DSM-5 development: Attenuated psychotic symptoms syndrome. Retrieved August 24, 2010, from
http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=412
.
4. Armenteros, J. L., & Davies, M. (2006). Antipsychotics in early onset schizophrenia: Systematic review and meta-analysis. European Child and Adolescent Psychiatry, 15, 141–148.
5. Armenteros, J. L., & Mikhail, A. G. (2002). Do we need placebos to evaluate new drugs in children with schizophrenia? Psychopharmacology, 159, 117–124.